2026 Safety Guide
Spironolactone Side Effects
Complete Spironolactone safety profile: reported side effects from published research, contraindications, severity tiers, and how to minimize adverse reactions through proper dosing and vendor selection.
Reported Spironolactone side effects
In acne and hair-loss trials Adverse reactions in the SAFA trial were slightly more common with spironolactone than with placebo, with more headaches (20 against 12 percent, p=0.02) and no serious adverse reactions (PMID: 37192767). In a 48-woman hair-loss pilot trial, adverse events, mainly menstrual irregularity (37.5 percent), were significantly more common with spironolactone than with placebo (PMID: 40978669). Adverse events were reported by 18.6 percent of women on spironolactone in a 204-woman trial comparing spironolactone with bicalutamide (PMID: 41742379). In a 120-woman trial, the group given topical minoxidil plus oral spironolactone reported the most adverse effects of three groups (PMID: 35899211). A 2025 meta-analysis of five placebo-controlled acne trials with 563 patients found no significant rise in menstrual irregularity or breast enlargement (PMID: 40823723). In an older survey of 54 patients taking spironolactone for hirsutism or acne, 91 percent had side effects, mostly menstrual disturbance and breast enlargement or tenderness, and 13 percent stopped the drug (PMID: 2969259). Potassium The US label warns that spironolactone can cause hyperkalemia, with higher risk in people with impaired kidney function and in those taking potassium supplements, potassium-containing salt substitutes or drugs such as ACE inhibitors and angiotensin receptor blockers (US prescribing information for Aldactone). Among 974 healthy young women taking spironolactone for acne, 13 of 1,802 potassium measurements (0.72 percent) were high, equivalent to the 0.76 percent background rate, and the authors concluded that routine monitoring was unnecessary in this group (PMID: 25796182). Among 398 women aged 45 or older taking spironolactone for skin conditions, high potassium occurred in 10.1 percent, and in 22.4 percent of those aged 65 or older; it was mild in 97.5 percent of cases (PMID: 41655839). After the RALES heart failure trial was published, spironolactone prescriptions and hospital admissions for hyperkalemia rose sharply among older Ontario patients with heart failure who were also taking ACE inhibitors (PMID: 15295047). Breast and hormonal effects In RALES, breast enlargement (gynecomastia) or breast pain occurred in 10 percent of men on spironolactone against 1 percent on placebo (PMID: 10471456). The current US label lists irregular menses or amenorrhea, postmenopausal bleeding, breast and nipple pain, decreased libido and trouble achieving or keeping an erection among reported reactions (US prescribing information for Aldactone). Cancer questions Older Aldactone labels carried a boxed warning based on tumors in rats fed spironolactone in the diet for 18 to 24 months, among them benign thyroid and testicular adenomas, liver changes, and thyroid follicular adenomas and carcinomas (US prescribing information for Aldactone). In a 2022 meta-analysis of seven studies with about 4.5 million people, most of them older adults, spironolactone use was not associated with breast cancer (risk ratio 1.04) and was associated with less prostate cancer (risk ratio 0.79), with very low certainty of evidence (PMID: 35138351). Among breast cancer survivors in a US insurance database, spironolactone was not associated with cancer recurrence after propensity matching (adjusted hazard ratio 0.966) (PMID: 32446820). Other reported reactions The current US label also lists gastric bleeding and ulcers, low white cell and platelet counts, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS), confusion, dizziness, hair loss (alopecia), and a very few cases of mixed liver injury with one death (US prescribing information for Aldactone).
When to continue, reduce, or stop Spironolactone
Mild: continue protocol
Transient mild symptoms (slight GI upset, minor injection-site reaction, brief fatigue) typically resolve within 3-7 days as physiology adjusts. Continue at current dose; monitor weekly.
Moderate: reduce dose
Persistent mild symptoms past two weeks, or new symptoms like sustained mood changes, sleep disruption, or appetite shifts. Reduce dose by 25-50% and reassess at the end of the next 2-week window.
Severe: discontinue + seek care
Any signal of allergic response (rash, swelling, breathing difficulty), unexplained chest discomfort, severe injection-site reaction with infection signs, or vision changes. Discontinue immediately and consult a licensed practitioner.
Spironolactone contraindications
The US label contraindicates spironolactone in people with hyperkalemia or Addison's disease and with concurrent use of eplerenone (US prescribing information for Aldactone). Hyperkalemia risk rises with impaired kidney function and with potassium supplements, salt substitutes, ACE inhibitors, angiotensin receptor blockers, NSAIDs, heparin and trimethoprim (US prescribing information for Aldactone). Women aged 65 or older taking spironolactone for skin conditions had more hyperkalemia than women aged 45 to 64 (PMID: 41655839). Spironolactone feminized male fetuses in rats, and the US label states that it should be avoided in pregnant women, or a pregnant woman told of the potential risk to a male fetus, because of its antiandrogenic properties (US prescribing information for Aldactone). Sudden shifts in fluid and electrolytes may bring on hepatic encephalopathy and coma in people with liver cirrhosis and ascites (US prescribing information for Aldactone). Gynecomastia or breast pain is a concern for men: it occurred in 10 percent of men taking spironolactone in RALES (PMID: 10471456). Low blood pressure calls for caution: among 432 women taking spironolactone with low-dose oral minoxidil, dizziness, lightheadedness or orthostatic symptoms occurred in 12.0 percent, and taking one or more other blood pressure drugs raised the odds of these effects (odds ratio 3.29) (PMID: 41654020). In competitive sport, spironolactone is on the World Anti-Doping Agency's list of substances prohibited at all times (WADA Prohibited List 2026).
Why vendor quality drives Spironolactone side-effect frequency
Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.
Full Spironolactone profile
Mechanism, dosing, half-life, peer-reviewed studies.
Spironolactone protocol
Three-tier dosing protocol with cycle structure.
Alternatives
If side-effect profile rules out Spironolactone for you, similar compounds.
Spironolactone side effects FAQ
What are the most common Spironolactone side effects?
In acne and hair-loss trials Adverse reactions in the SAFA trial were slightly more common with spironolactone than with placebo, with more headaches (20 against 12 percent, p=0.02) and no serious adverse reactions (PMID: 37192767). In a 48-woman hair-loss pilot trial, adverse events, mainly menstrual irregularity (37.5 percent), were significantly more common with spironolactone than with placebo
Are there severe side effects to watch for with Spironolactone?
Severe reactions are rare in published research but can occur. Watch for: allergic-type symptoms (rash, swelling, breathing difficulty), unexplained chest discomfort, infection signs at injection sites, vision changes, or severe persistent mood/sleep disruption. Any of these warrants immediate discontinuation and consultation with a licensed practitioner. The Severity Tiers section above triages mild → moderate → severe response patterns.
Does Spironolactone have contraindications?
The US label contraindicates spironolactone in people with hyperkalemia or Addison's disease and with concurrent use of eplerenone (US prescribing information for Aldactone). Hyperkalemia risk rises with impaired kidney function and with potassium supplements, salt substitutes, ACE inhibitors, angiotensin receptor blockers, NSAIDs, heparin and trimethoprim (US prescribing information for Aldactone
How can I minimize Spironolactone side effects?
Three biggest levers: (1) Start at the Beginner-tier dose for 2-3 weeks before escalating, which gives time to detect adverse signals at minimum effective dose. (2) Source from COA-verified vendors only: impurity profiles and mislabeled compounds drive a disproportionate share of reported side effects in research-compound communities. (3) Maintain adequate cycle off-time when applicable: receptor-saturating compounds benefit from 4-6 week breaks. The vendor section below lists the cheapest in-stock Spironolactone sources we track, each linked to its Trust Score (COA verification is 30% of the score).
Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.